same exact thing as my sister,but our ultimate goal was to have surgery although the oncologist said it was highly unlikely, she stopped doing chemo after the 1st round (it was way to hard on her) our oncologist here said a few months at best without treatment and she is at the start of her 7th month and doing better than we all expected, just glad we still have her,she is the best sister a guy could ask for and an awesome human being! everyday we get with her is truly a blessing. glad your husband is responding well with the chemo,and glad he is tolerating it so well, good luck and god bless

@sdd3460, I'm glad to hear your loved one is doing well so far. Do you mind if I ask what the clinical study immunology drug is that's being co-administered with Gem/Abrax, and if that's for a specific mutation like BRCA or PALB?

Also, this is kind of recent, long-shot stuff, but are you familiar with HAI (Hepatic Artery Infusion)? It's where surgeons implant a pump with a chemo reservoir that has a catheter directly to one of the arteries that feeds the liver.

This context of this video:

The video link above features Dr. Michael Cavner, who did his fellowship at MSKCC, and describes how the work there expanded as those fellows graduated and moved to new centers.

I noticed that a fairly new/young surgeon at Mayo Jacksonville, Dr. Katherine Poruk at lists HAI and Whipple among procedures she performs. She did her fellowship at MSKCC and co-published several papers with Dr. Christopher Wolfgang during her residency at Johns Hopkins, so she or someone with similar background might be a good person to discuss options with.
https://www.mayoclinic.org/biographies/poruk-katherine-m-d/bio-20545266
In Dr. Cavner's video, he mentions the importance of a pre-infusion saline test to make sure the chemo is _not_going to the pancreas (context again being to treat a colorectal met to the liver), but for someone with a tumor also in the pancreas, it might actually be desired and doable.

I had only read of direct arterial infusion for pancreatic cancers in rats, but they were able to obtain chemo concentrations in the pancreas with 1/300th the dose of what they needed for conventional systemic chemo through a port while minimizing systemic side effects.